<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A group of 47 patients up to 18 years of age, with primary non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the gastrointestinal tract, were investigated </plain></SENT>
<SENT sid="1" pm="."><plain>The lesions were located in the stomach (n = 2), small intestine (n = 17), the ileocecal region (n = 20), the large intestine (n = 7), and multifocally in the small and large intestines (n = 1) </plain></SENT>
<SENT sid="2" pm="."><plain>Of the patients, 41 were male and 6 were female; their age at presentation ranged from 2 to 18 years </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the cases belonged to the high-grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> group of the updated Kiel classification </plain></SENT>
<SENT sid="4" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was the most frequent histological type (n = 35), followed by <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 3), <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 2), lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), and large-cell anaplastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="5" pm="."><plain>Five of the patients had high-grade unclassified B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Of <z:hpo ids='HP_0000001'>all</z:hpo> the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types 41 cases (87%) were positive for Ki-B3 (a B-cell marker) </plain></SENT>
<SENT sid="7" pm="."><plain>Expression of monoclonal immunoglobulin was demonstrated in 8 of 35 cases (23%) of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in <z:hpo ids='HP_0000001'>all</z:hpo> 3 cases of <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in both cases of <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in the single case of lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in <z:hpo ids='HP_0000001'>all</z:hpo> 5 cases of high-grade unclassified B-cell non-Hodgkins <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Most of the Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> showed the light chain lambda (7/8) </plain></SENT>
<SENT sid="9" pm="."><plain>According to the staging classification of Murphy (N Engl J Med 299:1446-1448, 1978), 12% of the 34 cases available were stage IE, 44% stage IIE, 38% stage IIIE, and 6% stage IVE </plain></SENT>
<SENT sid="10" pm="."><plain>Of these 34 patients, 13 died with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> within 1 year after diagnosis </plain></SENT>
<SENT sid="11" pm="."><plain>The survival rate for the 19 patients in stages I and IIE at 2 years was 83%, while for the 15 patients in stages III and IVE it was 32% (P less than 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>A significant difference in survival was found between the 13 patients with primary involvement of the small intestine and the 20 patients with primary involvement of the large intestine and ileocecal region, the latter showing a better prognosis </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> type did not significantly influence survival </plain></SENT>
<SENT sid="14" pm="."><plain>Our findings indicate that the stage at diagnosis and the primary site are important prognostic features in gastrointestinal non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>